{"id":38498,"date":"2018-10-22T00:00:00","date_gmt":"2018-10-21T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/"},"modified":"2020-11-16T16:20:21","modified_gmt":"2020-11-16T15:20:21","slug":"aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/","title":{"rendered":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH"},"content":{"rendered":"<p>El ensayo cl\u00ednico, denominado AELIX-003, tiene como objetivo investigar, en individuos infectados por el VIH bajo terapia antirretroviral, la seguridad, tolerabilidad, inmunogenicidad y eficacia de un r\u00e9gimen compuesto por el <a href=\"http:\/\/www.aelixtherapeutics.com\/pipeline\/\" target=\"_blank\" rel=\"noopener noreferrer\">immunogen\u00a0HTI<\/a>\u00a0de AELIX Therapeutics \u2013que\u00a0genera una potente respuesta\u00a0inmunitaria mediante la cual las c\u00e9lulas T del sistema inmunitario reconocen las c\u00e9lulas infectadas por el virus y las eliminan\u2013 y<a href=\"http:\/\/www.gilead.com\/research\/pipeline\" target=\"_blank\" rel=\"noopener noreferrer\">\u00a0Vesatolimod<\/a>, un\u00a0antagonista\u00a0potente y selectivo del receptor\u00a0TLR7\u00a0de\u00a0Gilead\u00a0Sciences, que se administra de forma oral para activar directamente las c\u00e9lulas\u00a0dendr\u00edticas plasmocitoides.\u00a0<\/p>\n<p>En el estudio AELIX-003 se espera que Vesatolimod active la expresi\u00f3n del VIH en el cuerpo y aumente la respuesta inmune inducida por la vacuna, conduciendo as\u00ed a la eliminaci\u00f3n de las c\u00e9lulas infectadas por el virus. Actualmente, vesatolimod est\u00e1 bajo evaluaci\u00f3n cl\u00ednica por parte de Gilead en individuos infectados con el VIH con supresi\u00f3n viral.\u00a0<\/p>\n<p>\u00abEsta colaboraci\u00f3n combina la amplia experiencia de Gilead en el desarrollo de medicamentos antivirales con nuestra plataforma de vacunas altamente innovadora\u00bb, comenta el Dr. Ian McGowan, vicepresidente de Asuntos M\u00e9dicos de AELIX.<\/p>\n<p>\u201cEl mantenimiento de la remisi\u00f3n viral sin terapia antirretroviral representa la pr\u00f3xima frontera en el tratamiento del VIH. Estamos muy contentos de colaborar con Gilead en este proyecto, nuestro primer paso para mostrar el potencial de nuestro inmun\u00f3geno HTI como la base de reg\u00edmenes combinados para el mantenimiento de la remisi\u00f3n viral \u00ab, afirma el\u00a0Dr. Lance Berman, director m\u00e9dico de AELIX.<\/p>\n<p>\u00abGilead est\u00e1 comprometido con la investigaci\u00f3n y el desarrollo de nuevas terapias que puedan ayudar a informar de las posibles estrategias de cura para las personas que viven con el VIH\u00bb, declara John McHutchison, AO, MD,\u00a0i CSO de Gilead Sciences. \u00abEsta colaboraci\u00f3n reunir\u00e1 a dos prometedores agentes en fase de investigaci\u00f3n que ya se est\u00e1n evaluando de forma independiente en ensayos cl\u00ednicos de fase temprana. Gilead conf\u00eda en la colaboraci\u00f3n con AELIX Therapeutics en este innovador esfuerzo de investigaci\u00f3n cl\u00ednica\u00bb.<\/p>\n<p>\n<strong>\u25baM\u00e1s informaci\u00f3n: <a href=\"http:\/\/www.aelixtherapeutics.com\/2018\/10\/18\/gilead-science\/\" target=\"_blank\" rel=\"noopener noreferrer\">Web de AELIX Therapeutics [+]<\/a><\/strong><\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La compa\u00f1\u00eda de biotecnolog\u00eda en fase cl\u00ednica\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/empresa?p_p_id=detallempresa_WAR_empleatsempresesportlet&amp;p_p_state=MAXIMIZED&amp;_detallempresa_WAR_empleatsempresesportlet_empresaId=ENT_006855&amp;_detallempresa_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fes%2Fentitats\" target=\"_blank\" rel=\"noopener noreferrer\">AELIX Therapeutics<\/a>\u00a0\u2013con sede en el Parc Cient\u00edfic de Barcelona\u00a0y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH\u2013 ha firmado un acuerdo de colaboraci\u00f3n con Gilead Sciences, biofarmac\u00e9utica que descubre, desarrolla y comercializa medicamentos innovadores en \u00e1reas de necesidades m\u00e9dicas no cubiertas. Ambas empresas evaluar\u00e1n de forma conjunta productos de investigaci\u00f3n propios en un estudio cl\u00ednico estrat\u00e9gico destinado a conseguir una cura funcional contra la infecci\u00f3n por el VIH.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":24506,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-38498","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La compa\u00f1\u00eda de biotecnolog\u00eda en fase cl\u00ednica\u00a0AELIX Therapeutics\u00a0\u2013con sede en el Parc Cient\u00edfic de Barcelona\u00a0y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH\u2013 ha firmado un acuerdo de colaboraci\u00f3n con Gilead Sciences, biofarmac\u00e9utica que descubre, desarrolla y comercializa medicamentos innovadores en \u00e1reas de necesidades m\u00e9dicas no cubiertas. Ambas empresas evaluar\u00e1n de forma conjunta productos de investigaci\u00f3n propios en un estudio cl\u00ednico estrat\u00e9gico destinado a conseguir una cura funcional contra la infecci\u00f3n por el VIH. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-21T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:20:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"386\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH\",\"datePublished\":\"2018-10-21T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/\"},\"wordCount\":374,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16049214835fa9288bec87d.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/\",\"name\":\"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16049214835fa9288bec87d.jpeg\",\"datePublished\":\"2018-10-21T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:20:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16049214835fa9288bec87d.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/16049214835fa9288bec87d.jpeg\",\"width\":800,\"height\":386},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/","og_locale":"es_ES","og_type":"article","og_title":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona","og_description":"La compa\u00f1\u00eda de biotecnolog\u00eda en fase cl\u00ednica\u00a0AELIX Therapeutics\u00a0\u2013con sede en el Parc Cient\u00edfic de Barcelona\u00a0y especializada en el descubrimiento y desarrollo de inmunoterapias contra la infecci\u00f3n por el VIH\u2013 ha firmado un acuerdo de colaboraci\u00f3n con Gilead Sciences, biofarmac\u00e9utica que descubre, desarrolla y comercializa medicamentos innovadores en \u00e1reas de necesidades m\u00e9dicas no cubiertas. Ambas empresas evaluar\u00e1n de forma conjunta productos de investigaci\u00f3n propios en un estudio cl\u00ednico estrat\u00e9gico destinado a conseguir una cura funcional contra la infecci\u00f3n por el VIH. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2018-10-21T23:00:00+00:00","article_modified_time":"2020-11-16T15:20:21+00:00","og_image":[{"width":800,"height":386,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH","datePublished":"2018-10-21T23:00:00+00:00","dateModified":"2020-11-16T15:20:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/"},"wordCount":374,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/","url":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/","name":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg","datePublished":"2018-10-21T23:00:00+00:00","dateModified":"2020-11-16T15:20:21+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/10\/16049214835fa9288bec87d.jpeg","width":800,"height":386},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/aelix-therapeutics-y-gilead-sciences-establecen-un-acuerdo-de-colaboracion-en-investigacion-clinica-para-la-cura-del-vih\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"AELIX Therapeutics y Gilead Sciences establecen un acuerdo de colaboraci\u00f3n en investigaci\u00f3n cl\u00ednica para la cura del VIH"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=38498"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38498\/revisions"}],"predecessor-version":[{"id":44626,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38498\/revisions\/44626"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/24506"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=38498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=38498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=38498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}